PHARM: Joenja and RUCONEST fuel growth, with pipeline advances and $375—395M revenue projected for 2026

RUCONEST and Joenja drive strong commercial performance, with Joenja expanding into new indications and geographies. Napazimone advances in pivotal trials for mitochondrial disease. Financial guidance projects $375—395M revenue in 2026, with major clinical readouts expected in late 2026 and 2027.Or…